Research progress on adverse events in clinical treatment of anti-PD-1/PD-L1 antibodies

Although anti-PD-1/PD-L1 antibodies have been proved to be effective for a variety of cancers, meanwhile, it will also bring about immune related adverse events(irAEs)peculiar to tumor immunotherapy. This article mainly reviews the adverse reactions induced by anti-PD-1/PD-L1 antibodies and corresponding countermeasures, as well as the impact of adverse events on the prognosis of patients and other related hot issues.